Clinical Partners
David Avigan, M.D.
Principal Investigator, Clinical Trials
Dr. Avigan received his undergraduate degree from Columbia University and in 1989 completed his M.D. at Yale University School of Medicine. He did his internal medicine and residency training at Columbia Presbyterian Medical Center from 1989-1993, and from 1992-1993 he was the chief resident of Internal Medicine. From 1993-1996, he was a fellow, and later, chief fellow in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center and research fellow at Rockefeller University.
Dr. David Avigan joined the attending staff of Hematology/Oncology at Beth Israel Deaconess Medical Center in 1996 and became the director of the Hematological Malignancies and Bone Marrow Transplant Program in 1997 and the chief of Hematological Malignancies and Bone Marrow Transplant Section in 2014. He is a Professor of Medicine at Harvard Medical School. Dr. Avigan has established a translational research program for cancer vaccines at BIDMC as part of the Dana Farber Harvard Cancer Center.
Laboratory efforts have focused on the development of dendritic cell based vaccines including a model in which patient derived tumor cells are fused with dendritic cells as a novel patient specific vaccine. Based on these findings, he has supervised a series of clinical trials to examine the immunologic and clinical efficacy of this vaccine strategy for patients with hematologic malignancies and solid tumors. His work has been supported by grants from the National Cancer Institute, National Institutes of Health, Department of Defense, and Leukemia and Lymphoma Society.
Richard Stone, M.D.
Richard Stone, MD, is the Chief of Staff and Director of the Adult Acute Leukemia Program at Dana-Farber, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders and myelodysplastic syndrome [MDS] (a bone marrow failure state that may convert to leukemia).
In addition to his work at Dana-Farber, Stone serves as Chair of the Medical Oncology Board of the American Board of Internal Medicine, Chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation and Chairman of the Leukemia Core Committee for the national cooperative trials group the Alliance.
Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute.
Principal Investigator, Clinical Trials
Dr. Avigan received his undergraduate degree from Columbia University and in 1989 completed his M.D. at Yale University School of Medicine. He did his internal medicine and residency training at Columbia Presbyterian Medical Center from 1989-1993, and from 1992-1993 he was the chief resident of Internal Medicine. From 1993-1996, he was a fellow, and later, chief fellow in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center and research fellow at Rockefeller University.
Dr. David Avigan joined the attending staff of Hematology/Oncology at Beth Israel Deaconess Medical Center in 1996 and became the director of the Hematological Malignancies and Bone Marrow Transplant Program in 1997 and the chief of Hematological Malignancies and Bone Marrow Transplant Section in 2014. He is a Professor of Medicine at Harvard Medical School. Dr. Avigan has established a translational research program for cancer vaccines at BIDMC as part of the Dana Farber Harvard Cancer Center.
Laboratory efforts have focused on the development of dendritic cell based vaccines including a model in which patient derived tumor cells are fused with dendritic cells as a novel patient specific vaccine. Based on these findings, he has supervised a series of clinical trials to examine the immunologic and clinical efficacy of this vaccine strategy for patients with hematologic malignancies and solid tumors. His work has been supported by grants from the National Cancer Institute, National Institutes of Health, Department of Defense, and Leukemia and Lymphoma Society.
Richard Stone, M.D.
Richard Stone, MD, is the Chief of Staff and Director of the Adult Acute Leukemia Program at Dana-Farber, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders and myelodysplastic syndrome [MDS] (a bone marrow failure state that may convert to leukemia).
In addition to his work at Dana-Farber, Stone serves as Chair of the Medical Oncology Board of the American Board of Internal Medicine, Chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation and Chairman of the Leukemia Core Committee for the national cooperative trials group the Alliance.
Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute.
Research Partners
Collaborating with World’s Leading Research Institutions
Genus Oncology has partnered with premier cancer research institutions to advance our pipeline of novel, first-in-class, cancer immuno-therapeutic agents targeting MUC1-C oncoprotein, including:
Genus Oncology has partnered with premier cancer research institutions to advance our pipeline of novel, first-in-class, cancer immuno-therapeutic agents targeting MUC1-C oncoprotein, including:
|
|
|
|
